STAT6 decoy oligodeoxynucleotide (ODN)-containing ointment more potently inhibits mouse skin inflammation when formulated with ionic liquid technology than as a traditional Vaseline ointment

Handa, Yutaro; Ugajin, Tsukasa; Igawa, Ken; Hamamoto, Hidetoshi; Kobayashi, Katsunori; Komatsuno, Takao; Yamamoto, Toshinori; Kawahara, Kazuo; Yokozeki, Hiroo

doi:10.1016/j.alit.2018.12.011

Cited by 8 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If the problem of permeability can be solved, the utility of the strategy may be greatly improved in terms of therapeutic effects and economic aspects associated with the commercialisation of products (i.e., if efficacy with a small amount of nucleic acid can be achieved, costs can be reduced). Using novel technologies to enhance efficacy in terms of skin permeability, highly polymerised compounds such as STAT6 decoy ODNs have been introduced into skin cells, and an improved version of STAT6 decoy ODN ointment has been developed [46]. It was recently confirmed that this new technology facilitates the introduction of STAT6 decoy ODNs into the skin with significantly higher efficiency than was previously achieved [46].…”

Section: Nucleic Acid Drugs That Target Signal Transducer and Activatmentioning

confidence: 99%

“…Using novel technologies to enhance efficacy in terms of skin permeability, highly polymerised compounds such as STAT6 decoy ODNs have been introduced into skin cells, and an improved version of STAT6 decoy ODN ointment has been developed [46]. It was recently confirmed that this new technology facilitates the introduction of STAT6 decoy ODNs into the skin with significantly higher efficiency than was previously achieved [46].…”

Section: Nucleic Acid Drugs That Target Signal Transducer and Activatmentioning

confidence: 99%

See 1 more Smart Citation

Future trends in the treatment of atopic dermatitis

Igawa

2019

Immunological Medicine

Self Cite

View full text Add to dashboard Cite

Atopic dermatitis (AD) is caused by complex interactions between a variety of genetic and environmental factors that contribute to the maintenance of the chronic inflammatory skin condition. Most conventional treatments have been designed for the so-called 'average patient'. In recent years however, many previously unknown details pertaining to the mechanisms of the pathogenesis of AD have been elucidated, and novel treatments based on these pathological mechanisms or on subgroup classifications have been developed. Herein, how future treatment strategies for AD can be developed is described. ARTICLE HISTORY

show abstract

Section: Nucleic Acid Drugs That Target Signal Transducer and Activatmentioning

confidence: 99%

Section: Nucleic Acid Drugs That Target Signal Transducer and Activatmentioning

confidence: 99%

Future trends in the treatment of atopic dermatitis

Igawa

2019

Immunological Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…[144] Copyright 2020, Elsevier B.V. Maintain the stability of lysozyme [121] Improve targeting [121] Reduce immunogenicity [121] Nucleic acids BDOA Transdermal Adjustment to meet the ideal characteristics of transdermal drug delivery (Skin transport, cell internalization, and biocompatibility) [122] Maintain the structural integrity of siRNA [91] Facilitate the absorption of oligonucleotides (ODNs) [123] Vaccines [Chl][C18:1] Transdermal Improve the transdermal penetration [41] Enhance the anti-tumor effect of antigens [41] [Chl][La] Enhance the stability of antigen [124] Maintain the structural integrity of antigen [124] Enhance immune response to antigen [125] [ therapeutic peptides maintained good biocompatibility, stability, and drug loading. IL/O-NDs have the potential to be a promising carrier for the transdermal delivery of biomacromolecules.…”

Section: Ionic Liquid-peptides and Ionic Liquid-proteinsmentioning

confidence: 99%

Ionic Liquids: Momentous Tools in Transdermal Delivery of Biomacromolecules

Tai

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

Transdermal drug delivery is a promising strategy characterized by minor fluctuations in blood concentrations, few adverse effects, convenience, and excellent patient compliance, especially for biomacromolecules. Conversely, traditional delivery methods are limited by their poor penetration abilities and complex preparation and application techniques. However, some inherent properties of biomacromolecules, such as large sizes, complex structure, and poor stability, can affect their ability to overcome skin barriers and reach deeper layers. Ionic liquids (ILs) are organic salts composed of asymmetric cations and anions in liquid form below 100 °C. ILs provide excellent protection for biomacromolecules and can facilitate their passage through the stratum corneum to cells for therapeutic effects. Therefore, they represent one of the most promising approaches to promoting transdermal penetration. Here, the barriers to effective transdermal delivery, including skin properties and the stability and biocompatibility of IL‐based biomacromolecule formulations, are highlighted and the current status of IL‐based biomacromolecule formulations are focused on, the tremendous advantages of using ILs based on current challenges in transdermal drug delivery are discussed, and light is shed on several ILs frequently used in the delivery of biomacromolecules.

show abstract

Targeting cytokines and signaling molecules related to immune pathways in atopic dermatitis: therapeutic implications and challenges

Kim

2022

Arch. Pharm. Res.

View full text Add to dashboard Cite

STAT6 decoy oligodeoxynucleotide (ODN)-containing ointment more potently inhibits mouse skin inflammation when formulated with ionic liquid technology than as a traditional Vaseline ointment

Cited by 8 publications

References 10 publications

Future trends in the treatment of atopic dermatitis

Future trends in the treatment of atopic dermatitis

Ionic Liquids: Momentous Tools in Transdermal Delivery of Biomacromolecules

Targeting cytokines and signaling molecules related to immune pathways in atopic dermatitis: therapeutic implications and challenges

Contact Info

Product

Resources

About